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ABSTRACT	  
The	   efficacy	   of	   mineralocorticoid	   receptor	   (MR)	   antagonism	   in	   the	   treatment	   of	   certain	  
patients	  with	  heart	  failure	  has	  highlighted	  the	  pivotal	  role	  played	  by	  aldosterone	  and	  MR	  in	  
heart	  disease.	  The	  glucocorticoid	  receptor	  (GR)	  is	  also	  expressed	  in	  heart	  but,	  until	  recently,	  
the	  role	  of	  cardiac	  GR	  has	  received	  much	  less	  attention.	  GR	  and	  MR	  are	  highly	  homologous	  
in	   both	   structure	   and	   function,	   though	   not	   in	   cellular	   readout.	   Recent	   evidence	   in	   animal	  
models	   has	   uncovered	   a	   tonic	   role	   for	   glucocorticoid	   action	   via	   GR	   in	   cardiomyocytes	   in	  
prevention	   of	   heart	   disease.	   Here,	   we	   review	   this	   evidence	   and	   the	   implications	   for	   a	  
balance	   between	   GR	   and	   MR	   activation	   in	   the	   early	   life	   maturation	   of	   the	   heart	   and	   its	  
subsequent	  health	  and	  disease.	  	  
	  
Corticosteroid	  signalling	  in	  the	  heart	  	  
Corticosteroids	  -­‐	  glucocorticoids	  and	  mineralocorticoids	  -­‐	  are	  steroid	  hormones,	  synthesised	  
in	   the	   adrenal	   cortex.	   Mineralocorticoids	   (chiefly	   aldosterone)	   regulate	   electrolyte	   and	  
water	   balance.	   Physiological	   glucocorticoid	   hormones	   (predominantly	   cortisol	   in	   humans	  
and	   most	   other	   species,	   corticosterone	   in	   rats	   and	   mice)	   influence	   many	   physiological	  
processes,	   including	  development	  [1],	   immunity,	   inflammation	  and	  the	  stress	  response	  [2].	  
Corticosteroids	   exert	   most	   of	   their	   actions	   through	   two	   closely	   related	   members	   of	   the	  
nuclear	  receptor	  family:	  the	  glucocorticoid	  receptor	  (GR)	  and	  the	  mineralocorticoid	  receptor	  
(MR)	  [3,	  4].	  GR	  and	  MR	  show	  a	  high	  degree	  of	  sequence	  homology,	  particularly	  in	  the	  DNA	  
binding	   domain	   (they	   can	   bind	   the	   same	   DNA	   motif),	   yet	   the	   transcriptional	   and	  
physiological	  outcomes	  of	  GR	  activation	  are	  largely	  distinct	  from	  those	  of	  MR	  activation	  [5-­‐
7].	  With	  respect	  to	   ligand	  binding,	  GR	   is	  selective	  for	  glucocorticoids	  whereas	  MR	  is	  a	  high	  
affinity	   receptor	   for	   both	   aldosterone	   and	   physiological	   glucocorticoids.	   In	  
mineralocorticoid-­‐responsive	  epithelial	  cells,	  MR	  activation	  by	  aldosterone	  is	  enabled	  by	  its	  
co-­‐localisation	  with	  an	  enzyme,	  11β-­‐hydroxysteroid	  dehydrogenase	   (11β-­‐HSD)	   type	  2,	   that	  
	   3	  
by	  inactivating	  physiological	  glucocorticoids,	  allows	  preferential	  access	  of	  aldosterone	  to	  MR	  
[8].	   11β-­‐HSD2	   is	   absent	   in	   cardiomyocytes,	   though	   may	   be	   present	   at	   low	   levels	   in	   the	  
coronary	  vasculature	  [8].	  Thus,	  cardiac	  MR	  are	  potentially	  occupied	  and	  activated	  by	  either	  
mineralocorticoid	  or	  glucocorticoid	  hormones.	  The	  ramifications	  of	  this	  are	  discussed	  below.	  
Much	  of	  the	  interest	  in	  corticosteroid	  actions	  on	  the	  heart	  has	  focussed	  on	  MR,	  for	  obvious	  
reasons	  given	   its	  pathophysiological	   role	   (see	  below).	   In	  contrast,	   the	  role	  of	  GR	   in	  cardiac	  
health	   and	   disease	   has	   been	   less	   explored.	   Both	   glucocorticoid	   excess	   and	   insufficiency	  
affect	  the	  human	  heart.	  Indeed,	  Thomas	  Addison,	  in	  his	  description	  of	  adrenal	  insufficiency,	  
commented	   on	   “the	   remarkable	   feebleness	   of	   the	   heart’s	   action”	   [9].	   Conversely,	  
glucocorticoid	   excess	   in	   Cushing’s	   syndrome	   is	   associated	   with	   increased	   frequency	   of	  
cardiovascular	   events,	   including	   coronary	   heart	   disease	   and	   heart	   failure	   [10].	   However,	  
because	   glucocorticoids	   affect	  most	   systems	   (including	   blood	   pressure),	   establishing	   their	  
direct	   effects	   upon	   the	   heart	   and	   identifying	   those	  mediated	   by	   GR,	   has	   proved	   difficult.	  
Here	  we	   review	   recent	  data	  highlighting	   a	   key	   role	   for	  GR	   in	   the	  heart,	   both	   in	   utero	   and	  
postnatally,	  and	  discuss	  how	  an	  imbalance	  between	  GR	  and	  MR	  activation	  in	  cardiomyocytes	  
may	  contribute	  to	  cardiac	  dysfunction.	  	  
	  
An	  established	  role	  for	  MR	  and	  aldosterone	  in	  cardiovascular	  disease	  
A	  series	  of	  landmark	  clinical	  trials,	  including	  the	  RALES,	  EPHESUS	  and	  EMPHASIS-­‐HF	  studies,	  
have	  demonstrated	   that	  MR	  antagonism	   reduces	  mortality	   and	  morbidity	   in	   patients	  with	  
heart	   failure	  and	  reduced	  ejection	   fraction	   (HFREF)	   [11].	  However,	  MR	  antagonism	  had	  no	  
clinical	  benefits	  in	  patients	  with	  heart	  failure	  and	  preserved	  left	  ventricular	  ejection	  fraction	  
[12].	  The	  different	  outcomes	  in	  these	  trials	  observed	  in	  different	  patient	  groups	  may	  reflect	  
a	   more	   important	   role	   for	  MR	   antagonism	   in	   situations	   where	   the	   left	   ventricle	   (LV)	   has	  
impaired	  systolic	  function	  associated	  with	  myocardial	  scarring	  such	  as	  following	  myocardial	  
infarction	  (MI).	  The	  underlying	  mechanisms	  underpinning	  the	  benefits	  of	  MR	  antagonism	  in	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HFREF	  have	  been	  explored	  in	  human	  and	  animal	  studies.	  MR	  expression	  is	  increased	  in	  the	  
failing	   human	   heart	   [13]	   and	   in	   animal	  models	   of	   heart	   failure	   [14].	   Studies	   in	   transgenic	  
mice	   with	   tissue-­‐specific	   MR	   knockout	   (KO)	   have	   helped	   elucidate	   the	   normal	   and	  
pathophysiological	   role	   of	   MR	   in	   the	   heart	   (Figure	   1).	   These	   are	   discussed	   in	   several	  
excellent	   recent	   reviews	   [15,	   16],	   so	  will	   not	   be	  described	   in	   detail	   here.	   Suffice	   it	   to	   say,	  
cardiomyocyte-­‐specific	  disruption	  of	  MR	  in	  mice	  has	  minimal	  effect	  on	  basal	  heart	  function	  
and	   size,	   but	   improves	   infarct	   healing	   and	   prevents	   adverse	   cardiac	   remodeling	   and	  
contractile	   dysfunction	   in	   ischemic	   heart	   failure	   [17].	   It	   also	   protects	   against	   LV	   dilatation	  
and	   dysfunction	   in	   pressure	   overload	   following	   transverse	   aortic	   constriction.	   However,	  
these	   mice	   still	   develop	   fibrosis	   and	   cardiac	   hypertrophy	   [18],	   demonstrating	   that	   MR	  
activation	   in	   cardiomyocytes	   is	   not	   a	   pre-­‐requisite	   for	   cardiac	   fibrosis	   and	   hypertrophy	   in	  
this	  model.	  Another	  group	  has	  demonstrated	  that	  MR	  in	  cardiomyocytes	  is	  essential	  for	  the	  
cardiac	   fibrosis	   that	   occurs	  when	  mineralocorticoid	   levels	   are	   inappropriately	   high	   for	   salt	  
status	   [19].	  However,	   this	   is	   largely	  attributable	   to	   the	  need	   for	  MR	   in	  cardiomyocytes	   for	  
sustained	   inflammatory	   cell	   recruitment	   to	   the	   heart	   [19].	   In	   contrast,	   mice	   with	   MR	  
deletion	  in	  macrophages	  are	  protected	  from	  cardiac	  fibrosis	  in	  this	  experimental	  model	  and	  
in	   L-­‐NAME/AngII	   induced	   cardiac	   fibrosis	   [20,	   21].	   This	   suggests	   that	   MR	   activation	   in	  
macrophages	   causes	   the	   cardiac	   damage	   leading	   to	   fibrosis.	   Indeed,	   MR	   activation	   in	  
macrophages	  induces	  a	  classically	  activated	  (M1)	  pro-­‐inflammatory	  phenotype	  (the	  opposite	  
effect	  to	  GR	  activation),	  whereas	  KO	  of	  MR	  in	  macrophages	  results	  in	  polarisation	  more	  akin	  
to	   an	   alternatively	   activated,	   M2	   phenotype	   [21].	   Whether	   this	   reflects	   unopposed	   GR	  
activation	  in	  macrophages	  will	  be	  interesting	  to	  test.	  Macrophage	  MR	  may	  therefore	  be	  an	  
important	   target	   to	  prevent	  cardiac	   fibrosis	   [16,	  20,	  21].	  Thus,	   in	  animal	  models	  of	  cardiac	  
disease,	   MR	   is	   pro-­‐inflammatory.	   Transgenic	   over-­‐expression	   of	   MR	   in	   cardiomyocytes	  
disrupts	   electrical	   signalling.	   Approximately	   5-­‐fold	   elevation	   of	   MR	   in	   cardiomyocytes	  
prolongs	   the	  QT	   intervals	   of	   the	   electrocardiogram	   (ECG),	   causing	   ventricular	   arrhythmias	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and	   high	   mortality,	   preventable	   by	   MR	   antagonism	   [22].	   Similarly	   in	   humans,	   elevated	  
cardiac	  MR	   levels	   are	   associated	  with	   cardiac	   arrhythmias	   [23].	   Over-­‐expression	   of	  MR	   in	  
murine	  cardiomyocytes	  was	  not	  associated	  with	  cardiac	  fibrosis	  at	  two	  months	  of	  age	  [22],	  
suggesting	  that	  ion	  channel	  remodeling	  is	  a	  direct	  target	  of	  MR	  activation	  in	  cardiomyocytes,	  
with	   cardiac	   remodeling	   and	   fibrosis	   occurring	   secondarily.	   Thus,	   MR	   antagonism	   in	  
cardiomyocytes	  and	  macrophages	  may	  be	  beneficial	   in	  heart	   failure,	  where	  MR	  activation,	  
whether	  by	  cortisol	  or	  aldosterone	  or	   indeed	  both	  [24],	  contributes	  to	  disease	  progression	  
and	  mortality.	  
	  
Early	  life	  glucocorticoid	  action	  and	  cardiac	  resilience;	  a	  key	  role	  for	  GR	  
In	  mammals,	  the	  dramatic	  rise	  in	  glucocorticoid	  levels	  in	  late	  gestation	  is	  essential	  to	  survive	  
the	  transition	  to	  free	   living	  at	  birth	  [1].	  Thus,	  glucocorticoids	  are	  administered	  to	  pregnant	  
women	   at	   risk	   of	   pre-­‐term	   labour	   to	   help	   mature	   foetal	   tissues	   and	   improve	   neonatal	  
survival	   [25].	   Conversely,	   elevated	   or	   precocious	   exposure	   to	   glucocorticoids	   prenatally	  
retards	  foetal	  growth	  and	  increases	  risk	  of	  cardiovascular	  disease	  in	  adulthood	  [26,	  27].	  The	  
detrimental	  effect	  of	  excessive	   foetal	  glucocorticoid	  exposure	  may	  partly	  reflect	   the	  ability	  
of	  glucocorticoids	  to	  promote	  a	  switch	  from	  tissue	  accretion	  to	  differentiation	  [28].	  A	  trade-­‐
off	   between	   sufficient	   tissue	   accretion	   to	   be	   resilient	   to	   disease	   in	   adulthood,	   and	   the	  
requirement	  for	  cells	  to	  be	  sufficiently	  functionally	  mature	  to	  respond	  to	  stressful	  events	  in	  
the	   neonate,	   may	   account	   for	   the	   fact	   that	   both	   excessive	   and	   restricted	   perinatal	  
glucocorticoid	   signalling	   have	   a	   detrimental	   impact	   on	   cardiac	   health,	   albeit	   at	   different	  
stages	   of	   life	   [29].	   In	   support	   of	   this	   notion,	   glucocorticoid	   treatment	   improved	   cardiac	  
function	   in	   premature	   baboons	   with	   adrenal	   insufficiency	   [30].	   Antenatal	   glucocorticoid	  
treatment	  in	  preterm	  piglets	  both	  reduced	  the	  number	  of	  proliferating	  cardiomyocytes	  and	  
increased	   cardiomyocyte	   binucleation,	   compared	   with	   untreated	   preterm	   controls	   [31].	  
These	   data	   suggest	   that	   glucocorticoid	   treatment	   in	   premature	   infants	   promotes	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cardiomyocyte	   maturation	   at	   birth,	   but	   at	   the	   cost	   of	   fewer	   cardiomyocytes	   overall.	   In	  
neonatal	   rats,	   dexamethasone,	   a	  potent	   synthetic	   activator	  of	  GR,	   reduced	   cardiomyocyte	  
proliferation	   [32].	   The	   latter	   finding	   implicates	   glucocorticoid	   action	   through	   GR	   in	  
promoting	   the	   neonatal	   transition	   from	   hyperplastic	   to	   hypertrophic	   growth	   of	  
cardiomyocytes	   [33,	   34]	   This	   potentially	   explains	   how	   neonatal	   glucocorticoid	   treatment	  
limits	   cardiomyocyte	   reserve	  and	  promotes	  hypertrophic	   cardiac	  growth	   in	  adulthood	   [35]	  
(Figure	   2).	   MR	   activation	   in	   neonates	   may	   have	   the	   opposite	   effect	   and	   promote	  
cardiomyocyte	  proliferation	   (Figure	  2).	  Antagonism	  of	  MR	  with	   spironolactone	   in	  neonatal	  
rats	  reduced	  the	  number	  of	  proliferating	  myocytes,	  impairing	  cardiac	  growth	  [36].	  In	  foetal	  
sheep,	   cortisol	   increased	   cardiac	   cell	   proliferation,	   but	   via	   MR	   rather	   than	   GR	   [37].	   The	  
balance	   between	   GR	   and	   MR	   may	   be	   critical	   in	   determining	   the	   effects	   of	   physiological	  
glucocorticoids	   upon	   early	   life	   cardiac	   growth	   and	   subsequent	   adult	   cardiac	   health.	  
Especially	   given	   that	   MR	   in	   cardiomyocytes	   is	   likely	   to	   be	   predominantly	   occupied	   by	  
endogenous	   glucocorticoids,	   which	   circulate	   at	   >100	   fold	   higher	   concentrations	   than	  
aldosterone.	  	  	  
	  
Glucocorticoid	  action	   is	  essential	   for	   late	  gestation	  foetal	  heart	  maturation	   in	  mice	  [38].	   In	  
the	  embryonic	  zebrafish	  (Danio	  rerio)	  heart,	  GR	  is	  already	  activated	  5	  days	  post-­‐fertilisation	  
[39]	   suggesting	   the	   role	   of	   GR	   in	   mammalian	   heart	   development	   and	   maturation	   is	  
conserved	  from	  teleosts.	  In	  mice,	  cardiac	  GR	  is	  expressed	  from	  embryonic	  day	  (E)	  10.5	  but	  is	  
not	   normally	   activated	   until	   endogenous	   corticosterone	   levels	   rise	   at	   E15.5	   [38].	   Clearly	  
though,	   the	  expressed	  GR	  could	  be	  precociously	  activated	  by	  excessively	  high	  maternal	  or	  
exogenous	   glucocorticoid,	   prior	   to	   E15.5.	  Dexamethasone	   treatment	   of	   zebrafish	   embryos	  
from	   shortly	   after	   fertilisation	   promoted	   the	   maturation	   of	   the	   trabecular	   network	   and	  
underlying	   myofibril	   structure,	   and	   improved	   cardiac	   performance	   (assessed	   by	  
echocardiography)	   [40].	   Conversely,	   diminished	   glucocorticoid	   action	   (by	   morpholino-­‐
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mediated	   reduction	   in	   GR	   levels)	   impaired	   cardiac	   maturation,	   adversely	   affecting	   the	  
structure	   and	   function	   of	   the	   embryonic	   heart	   [40].	   Whether	   these	   effects	   were	   direct	  
within	   the	   heart	   or	   secondary	   to	   effects	   of	   GR	   knock-­‐down	   elsewhere	   was	   not	   tested.	  
Importantly	   though,	   these	   transient	  manipulations	   of	   glucocorticoid	   action	   in	   the	   embryo	  
programmed	  long-­‐term	  alterations	  in	  the	  adult	  heart	  [40].	  	  Similarly,	  foetal	  mice	  with	  global	  
or	   tissue-­‐specific	   (cardiomyocyte	   and	   vascular	   smooth	   muscle)	   disruption	   of	   GR	   show	  
impaired	  contractile	  function	   in	  utero	  at	  E17.5,	  associated	  with	  a	  failure	  of	  cardiomyocytes	  
to	   align	   properly	   in	   the	   outermost	   layer	   of	   the	   compact	  myocardium	  of	   the	   left	   ventricle.	  
Without	   GR,	   cardiomyocyte	   ultrastructure	   is	   abnormal	   with	   short	   disorganised	  myofibrils,	  
and	  at	  E17.5	  hearts	   show	  an	   immature	  gene	  expression	  profile	   that	  differs	   little	   from	  that	  
observed	   at	   E14.5,	   prior	   to	   the	   increase	   in	   corticosterone	   levels.	   Heart	   rate,	   however,	   is	  
normal	  [38].	  	  
	  
In	   vitro,	   treatment	   of	   foetal	   cardiomyocytes	   with	   physiologically	   relevant	   glucocorticoid	  
levels	   improves	  contractility	   (without	  affecting	   the	   frequency	  of	   spontaneous	  contraction),	  
promotes	  the	  appearance	  of	  mature	  myofibrils,	  and	  increases	  mitochondrial	  capacity.	  It	  also	  
induces	   expression	   of	   mRNAs	   regulated	   by	   glucocorticoids	   in	   vivo.	   These	   include	   genes	  
regulating	  energy	  metabolism	  and	  genes	  encoding	  calcium	  handling	  proteins:	  the	  ryanodine	  
receptor	   (RYR)-­‐2	   calcium-­‐induced	   calcium	   release	   channel,	   sarcoplasmic	   reticulum	   Ca2+-­‐
ATPase	   (SERCA2a),	   sodium-­‐calcium	   exchanger	   (NCX)-­‐1	   and	   the	   voltage-­‐dependent	   calcium	  
channel	   subunit	   Cav1.2	   [41].	   Treatment	   of	   foetal	   cardiomyocytes	   with	   dexamethasone,	   a	  
synthetic	   glucocorticoid	   that	   is	   a	   poor	   activator	   of	   MR	   [3],	   induced	   markers	   of	  
cardiomyocyte	  maturation.	  This	  was	  prevented	  by	  siRNA-­‐mediated	  knockdown	  of	  GR,	  or	  by	  
treatment	   with	   the	   GR	   antagonist	   RU486,	   but	   not	   the	   MR	   antagonist	   spironolactone,	  
demonstrating	  dependence	  on	  glucocorticoid	  signalling	  via	  GR	  not	  MR	   [41].	  Glucocorticoid	  
treatment	   also	   increases	   expression	   of	   master	   regulators	   of	   fatty	   acid	   oxidation	   in	   foetal	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cardiomyocytes,	  such	  as	  PPARα	  and	  lipin-­‐1	  [41],	  which	  are	  critical	  for	  mitochondrial	  energy	  
generation	   and	   heart	   function	   in	   neonates	   [42].	   Both	   in	   vivo	   and	   in	   vitro,	   glucocorticoids	  
induce	   the	   Ppargc1a	   gene	   (encoding	   PPARγ	   co-­‐activator-­‐1α;	   PGC-­‐1α).	   In	   vitro,	   siRNA-­‐
mediated	   knockdown	   of	   PGC-­‐1α	   in	   foetal	   cardiomyocytes	   abolished	   the	   ability	   of	  
glucocorticoid	   to	   induce	   changes	   in	   myofibril	   structure	   and	   mitochondrial	   oxygen	  
consumption	   [41],	   suggesting	   that	   PGC-­‐1α	   mediates	   at	   least	   some	   of	   the	   effects	   of	  
glucocorticoids	  in	  foetal	  cardiomyocyte	  maturation.	  Recent	  studies	  in	  mice	  have	  shown	  that	  
neonatal	   cell	   cycle	   arrest	   in	   cardiomyocytes	   is	   triggered	   by	   the	   increase	   in	  mitochondrial	  
reactive	   oxygen	   species	   (ROS)	   production	   and	  oxidative	  DNA	  damage	   that	   accompany	   the	  
increased	   mitochondrial	   activity	   in	   cardiomyocytes	   following	   birth	   [43].	   Dexamethasone	  
induces	  oxidative	  stress	  in	  hearts	  of	  neonatal	  rats	  [44].	  In	  human	  embryonic	  stem	  cell	  (hESC)	  
derived	  cardiomyocytes,	  PGC-­‐1α	  increases	  mitochondrial	  activity	  and	  the	  production	  of	  ROS	  
[45].	   Together	   these	   findings	   suggest	   that	   induction	   of	   PGC-­‐1α	   underlies	   the	   anti-­‐
proliferative	   effect	   of	   glucocorticoid	   treatment	   in	   neonatal	   cardiomyocytes	   through	  
increased	  mitochondrial	  capacity	  and	  ROS	  production.	   It	  will	  be	   important	   to	  establish	   the	  
optimal	   time	  window	   for	   glucocorticoid	   treatment	   in	   late	   gestation/early	   neonatal	   life,	   in	  
order	   to	   promote	   maturation	   of	   premature	   myocardial	   structure	   and	   function	   whilst	  
minimising	  future	  risk	  of	  cardiovascular	  disease.	  
	  
Cardiomyocyte	  GR	  maintains	  systolic	  function	  and	  prevents	  cardiac	  disease	  in	  adulthood	  
Recent	  studies	  in	  mice	  with	  cardiomyocyte-­‐specific	  deletion	  of	  GR,	  and	  in	  mice	  with	  specific	  
deletion	   of	   GR	   in	   both	   vascular	   smooth	   muscle	   cells	   and	   cardiomyocytes,	   have	  
demonstrated	  the	  pathological	  consequences	  of	  reduced	  GR	  signalling	  in	  the	  adult	  heart	  [46,	  
47].	  Both	  models	  show	  cardiac	  hypertrophy	  in	  adulthood	  and	  up-­‐regulation	  of	  myosin	  heavy	  
chain-­‐β,	   a	   marker	   of	   pathological	   cardiac	   remodeling	   [46,	   47].	   Mice	   with	   GR	   ablation	  
restricted	   to	   cardiomyocytes	   appeared	   normal	   in	   early	   life	   but	   developed	   left	   ventricular	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systolic	  dysfunction	  at	  three	  months	  of	  age	  and	  died	  early	  from	  congestive	  heart	  failure,	  in	  
the	   absence	   of	   cardiac	   fibrosis	   [46].	   The	   ECG	   did	   not	   differ	   significantly	   from	   controls.	  
Cardiac	  expression	  of	  several	  key	  genes,	  including	  Ryr2,	  was	  decreased	  prior	  to	  the	  onset	  of	  
symptoms,	   suggesting	   a	   causal	   role	   in	   the	   phenotype.	   Interestingly,	   a	   number	   of	   genes	  
associated	   with	   inflammation	   were	   up-­‐regulated	   in	   hearts,	   prior	   to	   the	   appearance	   of	  
symptoms,	  suggesting	  GR	  normally	  suppresses	  inflammation	  within	  the	  heart.	  This	  contrasts	  
with	   the	   pro-­‐inflammatory	   effects	   of	   MR	   activation	   in	   cardiomyocytes,	   at	   least	   under	  
pathological	   conditions	   [16].	   The	   adult	   phenotype	  of	  mice	  with	   deletion	   of	  GR	   in	   vascular	  
smooth	  muscle	  cells	  and	  cardiomyocytes	  remains	  to	  be	  fully	  reported,	  but	  early	  indications	  
suggest	  that	  the	  cardiac	  phenotype	  differs	  somewhat	  from	  the	  more	  restricted	  GR	  knockout,	  
with	  modestly	   elevated	   cardiac	   collagen	  and	  pro-­‐fibrotic	   signalling,	   potentially	  driven	  by	   a	  
compensatory	  increase	  in	  cardiac	  MR	  expression	  [47].	  	  
	  
Transgenic	  overexpression	  of	  GR	  restricted	  to	  adult	  cardiomyocytes	  caused	  bradycardia	  and	  
chronic	   atrio-­‐ventricular	   block	   in	  mice	   [48].	   Yet,	   in	   contrast	   to	   over-­‐expression	   of	  MR,	  GR	  
over-­‐expression	   was	   not	   associated	   with	   arrhythmia	   or	   early	   death,	   nor	   did	   it	   result	   in	  
cardiac	   hypertrophy	   or	   fibrosis	   (Figure	   1).	   The	   atrio-­‐ventricular	   block	  was	   associated	  with	  
ECG	   abnormalities	   distinct	   from	   those	   induced	   by	   MR	   over-­‐expression:	   PQ,	   QRS	   and	   QT	  
intervals	   were	   all	   increased	   [48].	   In	   vitro,	   cardiomyocytes	   from	   GR	   over-­‐expressing	   mice	  
showed	   major	   ion	   channel	   remodeling	   and	   alterations	   in	   calcium	   homeostasis,	   including	  
increased	  sarcoplasmic	  reticulum	  Ca2+	  load	  [48].	  Whilst	  cardiac	  MR	  over-­‐expression	  affected	  
mainly	   Ca2+	   current,	   GR	   over-­‐expression	   affected	   mainly	   Na+	   and	   K+	   currents,	   possibly	  
underlying	   the	   difference	   in	   susceptibility	   to	   arrhythmia	   between	   the	   two	   models.	   In	  
neonatal	   cardiomyocytes	   in	   vitro,	   not	   surprisingly,	   aldosterone	   induction	  of	   L-­‐type	  calcium	  
currents	   required	  MR,	  not	  GR	   [49].	  However,	   the	   receptor	   requirement	   for	   L-­‐type	  calcium	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current	   induction	   (and	   regulation	   of	   other	   ion	   channels)	   by	   corticosterone,	   arguably	   the	  
more	  relevant	  ligand,	  was	  not	  tested.	  	  
	  
Prior	   administration	   of	   glucocorticoid	   is	   cardioprotective	   in	   a	  mouse	  model	   of	  myocardial	  
infarction,	  with	  concurrent	  GR	  blockade	   increasing	   infarct	  size	   [50].	  However,	  GR	  blockade	  
following	  MI	  attenuates	  LV	  remodeling	   [51].	  Whether	   these	  effects	  are	  mediated	  by	  GR	   in	  
cardiomyocytes	  or	  instead	  reflect	  glucocorticoid	  actions	  on	  the	  vasculature	  or	  immune	  cells,	  
remains	   unclear.	   A	   preliminary	   report	   suggests	   that	   myeloid	   cell	   KO	   of	   GR	   reduces	   the	  
number	   of	   infiltrating	   monocytes/macrophages	   in	   the	   healing	   myocardium	   following	   MI,	  
associated	   with	   reduced	   neoangiogenesis	   in	   the	   damaged	   myocardium,	   greater	   infarct	  
expansion	   and	   an	   increase	   in	   mortality	   [52].	   It	   will	   be	   important	   to	   use	   the	   recently	  
developed	   GR	   KO	   mice	   (immune	   cells/cardiomyocytes)	   to	   fully	   define	   the	   role	   of	   GR	   in	  
models	  of	  myocardial	  infarction	  and	  other	  cardiac	  disease.	  Genetic	  evidence	  in	  humans	  also	  
supports	  an	  association	  between	  GR	  and	  heart	  disease.	  A	  common	  GR	  gene	  haplotype	  linked	  
to	  relative	  glucocorticoid	  resistance	  is	  associated	  with	  systolic	  dysfunction	  and	  heart	  failure	  
in	  adults	  [53-­‐55],	  and	  with	  increased	  systolic	  blood	  pressure	  and	  heart	  growth	  in	  childhood	  
[56].	  	  
	  
The	  critical	  cardiac	  MR/GR	  balance	  
Transgenic	  models	  tell	  us	  what	  is	  possible,	  not	  necessarily	  what	  happens	  in	  a	  physiological	  or	  
pathophysiological	  setting.	  Removing	  GR	  or	  MR	  from	  cardiomyocytes,	  or	  over-­‐expression	  of	  
either	   receptor,	   disrupts	   the	   normal	   GR/MR	   balance	   that	   may	   be	   critical	   in	   determining	  
outcome	   of	   corticosteroid	   action	   upon	   the	   heart.	   MR	   in	   the	   human	   heart	   are	   normally	  
occupied	  by	  cortisol	  rather	  than	  aldosterone	  [57],	  thus	  both	  MR	  and	  GR	  in	  cardiomyocytes	  
are	   predominantly	   occupied	   by	   glucocorticoid.	   The	   outcome	   of	   glucocorticoid	   action	   in	  
cardiomyocytes	   will	   depend	   upon	   several	   factors.	   MR	   is	   a	   higher	   affinity	   receptor	   for	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glucocorticoids	   than	   GR.	   It	   is	   likely	   to	   be	   fully	   occupied,	   even	   at	   diurnal	   nadir	   levels	   of	  
cortisol/corticosterone,	  though	  cellular	  redox	  conditions	  appear	  key	  in	  determining	  whether	  
glucocorticoid	   occupancy	   of	   MR	   leads	   to	   receptor	   activation	   [58].	   In	   contrast,	   GR	   is	   only	  
likely	   to	  be	   fully	  bound	  by	   ligand	  at	   the	  diurnal	  peak,	  or	   following	   stress.	  Additionally,	   the	  
relative	   density	   of	   GR	   and	   MR	   may	   be	   important	   in	   determining	   the	   outcome	   of	  
glucocorticoid	  action	   in	  cardiomyocytes.	  MR	  antagonism	  may	  be	  beneficial	   in	  heart	   failure	  
through	   altering	   the	   balance	   between	   MR	   and	   GR	   activity	   in	   favour	   of	   GR,	   even	   at	   the	  
natural	  cortisol	  nadir.	  For	  example,	  cardiac	  RYR	  activity	  is	  increased	  with	  over-­‐expression	  or	  
activation	  of	  MR	  in	  cardiomyocytes	  [59].	  This	  could	  lead	  to	  aberrant	  calcium	  release	  during	  
diastole	  and	  contribute	  to	  ventricular	  arrhythmias,	  without	  any	  alteration	  in	  RYR	  expression.	  
On	  the	  other	  hand,	  deletion	  of	  GR	  in	  cardiomyocytes	  reduces	  Ryr2	  mRNA	  levels	  [46].	  Thus,	  
both	   MR	   and	   GR	   signalling	   impact	   upon	   calcium-­‐induced	   calcium	   release,	   but	   through	  
different	   mechanisms	   and	   with	   potentially	   different	   consequences.	   Altering	   the	   balance	  
between	   GR	   and	   MR	   density,	   particularly	   during	   stress	   or	   when	   aldosterone	   levels	   are	  
elevated,	  is	  likely	  to	  affect	  both	  RYR	  density	  and	  activity,	  potentially	  generating	  arrhythmias.	  
Like	   the	   heart,	   the	   hippocampus	   co-­‐expresses	   MR	   and	   GR	   without	   11β-­‐HSD2.	   Reduced	  
hippocampal	   GR	   density	   or	   increased	   hippocampal	   MR	   density	   independently	   affect	  
cognitive	   behaviour,	   but	   interact	   to	   control	   hypothalamic-­‐pituitary-­‐adrenal	   axis	   activity	  
under	   stressful	   conditions	   [60].	  This	   suggests	   that	   for	   some	  key	  physiological	   systems,	   it	   is	  
the	  balance	  between	  GR	  and	  MR,	  rather	  than	  the	  absolute	  levels	  of	  either,	  that	  is	  critical	  for	  
outcome.	  Most	  corticosteroid-­‐regulated	  genes	   in	   the	  hippocampus	  are	   regulated	  either	  by	  
activated	  MR	  or	  by	  activated	  GR,	  with	  only	  a	  few	  responsive	  to	  both	  activated	  GR	  and	  MR	  
[6].	  Nevertheless,	  the	  actions	  may	  be	  inter-­‐dependent	  [60].	  A	  similar	  situation	  may	  apply	  in	  
cardiomyocytes;	   over-­‐expression	   of	   either	   GR	   or	   MR	   in	   cardiomyocytes	   in	   vivo	   affected	  
distinct	  gene	  networks,	  with	  only	  a	   few	  genes	  modulated	  by	  both	   [59].	  Thus,	   some	  of	   the	  
effects	  of	  GR	  or	  MR	  activation	  in	  cardiomyocytes	  may	  be	  distinct,	  but	  some	  may	  depend	  on	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the	  density	  and/or	  the	  activation	  of	  the	  other	  receptor.	  Intriguingly,	  adult	  carriers	  of	  loss-­‐of-­‐
function	   mutations	   in	   the	   NR3C2	   gene	   encoding	   MR	   show	   no	   sign	   of	   cardiac	   fibrosis	   or	  
remodeling,	  and	  have	  better	  diastolic	   LV	   function	   than	  normal	   individuals,	  despite	   lifelong	  
elevated	   circulating	   aldosterone	   levels	   [61].	   This	   suggests	   that	   reduced	  MR	   density	   in	   the	  
context	  of	  normal	  GR	  limits	  the	  adverse	  effects	  of	  hyperaldosteronism.	  Individuals	  with	  GR	  
(NR3C1)	   haploinsufficiency	   have	   been	   described	   [53,	   62],	   but	   their	   cardiac	   phenotype	   has	  
not	  been	  reported.	  	  
	  
Cardiac	  glucocorticoid	  concentrations	  can	  be	  regulated	  by	  local	  glucocorticoid	  metabolism	  
Finally,	   it	   is	   worth	   considering	   the	   impact	   of	   glucocorticoid	  metabolism	   within	   the	   heart.	  
Whereas	  11β-­‐HSD2	  is	  not	  expressed	  postnatally	  in	  cardiomyocytes,	  the	  type	  1	  isozyme,	  11β-­‐
HSD1,	   is.	   11β-­‐HSD1	   regenerates	   active	   cortisol/corticosterone	   from	   intrinsically	   inert	  
cortisone/11-­‐dehydrocorticosterone,	   thus	   potentially	   supplying	   ligand	   to	   cardiac	   receptors	  
(either	  GR	  or	  MR)	  [8,	  63].	  Mice	  with	  global	  KO	  of	  11β-­‐HSD1	  and	  also	  mice	  with	  tissue-­‐specific	  
KO	  in	  cardiomyocytes	  and	  vascular	  smooth	  muscle	  show	  mild	  diastolic	  dysfunction,	  possibly	  
due	  to	  reduced	  expression	  of	  SERCA2a,	   impairing	  relaxation	  of	  cardiomyocytes	  [63].	  Again,	  
calcium	  handling	  is	  affected	  with	  this	  alteration	  in	  intracellular	  glucocorticoid	  metabolism.	  In	  
this	   case	   though,	   both	   MR	   and	   GR	   expression	   are	   normal,	   and	   calcium	   uptake	   into	   the	  
sarcoplasmic	  reticulum	  is	  implicated.	  Mice	  lacking	  11β-­‐HSD1	  show	  greater	  inflammatory	  cell	  
recruitment	   following	   coronary	   artery	   ligation	   and	   myocardial	   injury,	   yet	   have	   a	   greater	  
angiogenic	   response	   to	   injury,	   and	   regain	   more	   cardiac	   function	   than	   control	   mice	   [64].	  	  
Presumably	   these	   effects	   are	   due	   to	   reduced	   local	   regeneration	   of	   active	   glucocorticoids	  
Interestingly	  though,	  the	  greater	  angiogenic	  response	  and	  better	  recovery	  of	  heart	  function	  
following	  MI	   are	   not	   seen	   in	  mice	  with	   KO	  of	   11β-­‐HSD1	   restricted	   to	   cardiomyocytes	   and	  
vascular	   smooth	  muscle	  cells	   [65],	   suggesting	   these	  beneficial	  effects	  may	  be	  mediated	  by	  
immune	   cells	   or	   perhaps	   cardiac	   fibroblasts.	   Whether	   all	   of	   these	   effects	   are	   mediated	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through	   attenuated	   activation	   of	   GR	   (the	   neoangiogenesis	   is	   [66]),	   or	   whether	   MR	   also	  
contributes,	  will	  be	  important	  to	  dissect	  with	  the	  potential	  for	  future	  targeting	  of	  therapies.	  
	  
Concluding	  remarks	  and	  future	  perspectives	  
Most	   of	   the	   attention	   to	   date	   has	   focussed	   on	  MR	   and	   its	   activation	   in	   the	   heart,	   but	   as	  
discussed	   here,	   a	   vital	   requirement	   has	   emerged	   for	   GR	   in	   promoting	   cardiomyocyte	  
maturation	   and	   in	   preventing	   heart	   disease.	  Much	   of	   this	   new	   evidence	   arises	   from	  mice	  
with	   alterations	   of	   GR	   or	   MR	   in	   specific	   cell	   types.	   In	   cardiomyocytes	   as	   well	   as	   in	  
monocytes/macrophages,	  the	  roles	  of	  GR	  and	  MR	  may	  be	  largely	  opposing.	  Both	  receptors	  
may	   be	   important	   in	   the	   trajectory	   of	   heart	   growth	   and	  maturation,	   possibly	   influencing	  
cardiac	   resilience	   in	   adulthood.	   Both	   clearly	   regulate	   ion	   channels,	   though	   differentially.	  
Both	  alter	  processes	  of	  heart	  repair	  and	  remodeling.	  Just	  how,	  will	  be	  important	  to	  discover,	  
especially	   in	  models	   of	   cardiac	   injury	   in	  which	   the	   cell-­‐specific	   role	   of	  GR	  has	   so	   far	   been	  
little	   explored.	   KO	  models,	  whilst	   very	  powerful,	   have	   their	   limitations.	   They	   represent	   an	  
“all	   or	   none”	   manipulation	   within	   certain	   cell	   types,	   in	   the	   context	   of	   a	   largely	   normal	  
environment	   elsewhere,	   and	   compensatory	   mechanisms	   may	   arise.	   Indeed,	   the	  
physiological	   consequence	   of	   over-­‐expressing	   GR	   or	   MR	   in	   cardiomyocytes	   is	   not	   the	  
opposite	  to	  KO	  of	  the	  respective	  receptor.	  Unpicking	  the	  relationship	  between	  MR	  and	  GR	  
within	  the	  cells	  that	  constitute	  the	  heart	  and	  repair	   it	   following	   injury,	  will	  be	  essential	   for	  
our	  future	  understanding	  of	  the	  pathophysiological	  roles	  of	  corticosteroids	  in	  the	  heart.	  The	  
importance	  of	  the	  balance	  between	  cardiac	  MR	  and	  GR	  density	  and/or	  activation	  is	  an	  area	  
ripe	  for	  investigation	  (see	  Outstanding	  Questions	  box).	  	  
	  
Dynamic	   studies	   of	   intracellular	   glucocorticoid	   availability	   and	   binding	   within	   heart	   are	  
possible	  [57].	  Establishing	  the	  outcome	  of	  glucocorticoid	  binding	  to	  cardiac	  MR	  in	  a	  variety	  
of	  physiological	   and	  pathophysiological	   situations	  will	   be	  difficult,	   but	   is	   a	   key	  question	   to	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address.	  Structural	  studies	  may	  tell	  us	  why	  the	  outcome	  of	  glucocorticoid	  occupation	  of	  MR	  
appears	   to	  depend	  on	   the	   cellular	   context.	  Glucocorticoid	   levels	   in	   the	   circulation	  depend	  
upon	   the	   activity	   of	   the	   HPA	   axis	   and	   also	   upon	   clearance	   rates.	   Intracellular	   levels,	  
however,	   can	   be	   boosted	   by	   11β-­‐HSD1.	   The	   importance	   of	   11β-­‐HSD1-­‐mediated	  
glucocorticoid	   amplification	  depends	  upon	   levels	   of	   its	   substrate,	   generated	  by	   renal	   11β-­‐
HSD2:	  highest	  when	  the	  HPA	  axis	  is	  activated	  [67].	  Thus,	  whilst	  MR	  are	  an	  established	  target	  
in	   heart	   failure,	   regulation	   of	   intracellular	   glucocorticoid	   levels	   by	   11β-­‐HSD1	   may	   also	  
represent	  an	  important	  therapeutic	  target	  in	  the	  future.	  	  
	  
With	  greater	  understanding	  of	  the	  relationship	  between	  GR	  and	  MR	  activation	  in	  specific	  cell	  
types	   will	   come	   better	   prospects	   for	   targeted	   therapies	   for	   cardiac	   injury	   and	   disease	   –	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Figure	  legends	  
Figure	  1:	  Murine	   studies	   illustrating	   the	   contrasting	   effects	  of	   altered	   cardiomyocyte	  GR	  
and	  MR	   receptor	   levels	   in	  adulthood.	  GR	  KO	  studies	   in	  mice	  show	  that	  GR	  is	  essential	   for	  
the	  maturation	  of	  cardiac	  structure	  and	  function	  in	  utero.	  Cardiomyocyte-­‐specific	  deletion	  of	  
GR	   results	   in	   pathological	   cardiac	   remodeling	   and	   left	   ventricular	   systolic	   dysfunction	   in	  
adulthood	  (right).	  In	  contrast,	  a	  reduction	  in	  cardiac	  MR	  levels	  is	  not	  detrimental	  under	  basal	  
condition,	  and	  can	  limit	  pathological	  cardiac	  remodeling	  following	  infarction	  and	  transverse	  
aortic	   constriction,	   and	   in	   ischemic	  heart	   failure	   (left).	   Elevated	  MR	  expression	   is	   found	   in	  
the	  failing	  human	  heart	  and	  in	  rodent	  models	  of	  heart	  failure.	  Cardiac	  overexpression	  of	  MR	  
in	  mice	  disrupts	  electrical	  signal	  leading	  to	  arrhythmias,	  which	  may	  underlie	  the	  high	  rate	  of	  
death	  in	  this	  model	  (centre	  left).	  Elevated	  GR	  expression	  in	  the	  murine	  heart	  causes	  distinct	  
electrocardiogram	  abnormalities	   compared	  with	  MR	  overexpression,	   including	  bradycardia	  
and	  atrio-­‐ventricular	  block	  (centre	  right),	  which	  in	  vitro	  studies	  suggest	  result	  from	  major	  ion	  
channel	  remodeling	  in	  cardiomyocytes.	  These	  studies	  highlight	  the	  importance	  of	  achieving	  
the	  correct	  GR/MR	  balance	  in	  maintaining	  cardiac	  health	  and	  limiting	  disease	  progression.	  	  
	  
Figure	  2:	  Modulating	  GR	  and	  MR	  signalling	  may	   influence	  the	  balance	  between	  neonatal	  
cardiomyocyte	  proliferation	  (hyperplasia)	  and	  later	  cardiomyocyte	  growth	  (hypertrophy).	  
Growth	  curves	  representing	  cardiomyocyte	  number	  (dashed	  curves)	  and	  cardiomyocyte	  cell	  
size	  (solid	  curves).	  Cardiomyocytes	  switch	  from	  hyperplasic	  to	  hypertrophic	  growth	  in	  early	  
neonatal	   life	   (red	   curves).	   Animal	   studies	   suggest	   that	   neonatal	   MR	   activation	   promotes	  
cardiomyocyte	  proliferation	  (hyperplastic	  growth)	  whilst	  limiting	  increases	  in	  cardiomyocyte	  
size	  (hypertrophic	  growth;	  pale	  blue	  curves).	  This	  is	  predicted	  to	  result	  in	  a	  greater	  number	  
of	   smaller	   cardiomyocytes	   in	   adulthood.	   Neonatal	   GR	   activation	  may	   reduce	   proliferative	  
cardiomyocyte	   growth	   and	   promote	   hypertrophic	   growth	   (dark	   blue	   curves).	   This	   is	  
predicted	   to	   lead	   to	   fewer	   but	   larger	   cardiomyocytes	   in	   adulthood.	  We	   hypothesise	   that	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alterations	   in	   the	   MR/GR	   balance	   might	   influence	   the	   switch	   from	   hyperplastic	   to	  
hypertrophic	   cardiomyocyte	  growth	   in	  neonates.	  This	   is	  predicted	   to	  affect	   cardiomyocyte	  
reserve	  in	  adulthood	  and	  may	  influence	  risk	  of	  cardiac	  disease.	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Trends	  box	  	  
• Glucocorticoids	  (steroid	  hormones)	  bind	  to	  glucocorticoid	  receptor	  (GR)	  and	  
mineralocorticoid	  receptor	  (MR)	  in	  cardiomyocytes.	  A	  role	  for	  MR	  in	  heart	  disease	  is	  
established.	  Recent	  work	  in	  mice	  shows	  GR	  also	  plays	  important	  roles	  in	  cardiac	  
health	  and	  disease.	  
• Antenatally,	  glucocorticoid	  action,	  via	  GR,	  is	  crucial	  for	  the	  functional	  maturation	  of	  
the	  fetal	  heart	  in	  preparation	  for	  birth.	  	  
• In	  neonates,	  glucocorticoid	  action	  may	  influence	  the	  timing	  of	  the	  switch	  	  from	  
proliferative	  cardiomyocyte	  growth	  to	  cell	  cycle	  exit,	  binucleation	  and	  hypertrophic	  
growth.	  
• In	  adulthood,	  GR	  plays	  a	  tonic	  role	  in	  cardiac	  health,	  preventing	  cardiomyopathy	  and	  
early	  death.	  	  	  
• GR	  and	  the	  related	  MR	  may	  act	  in	  a	  yin-­‐yang	  manner	  in	  cardiomyocytes,	  each	  
influencing	  the	  action	  of	  the	  other.	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Outstanding	  Questions	  box	  
• GR	  are	  essential	  for	  cardiac	  maturation	  in	  utero.	  Do	  glucocorticoids	  promote	  
cardiomyocyte	  cell	  cycle	  arrest,	  binucleation	  and	  hypertrophic	  growth	  in	  late	  
gestation	  and	  early	  neonatal	  life?	  What	  is	  the	  optimal	  time	  window	  and	  dose	  for	  
both	  antenatal	  and	  postnatal	  glucocorticoid	  treatment	  in	  order	  to	  minimise	  
cardiovascular	  disease	  risk	  in	  adulthood?	  
• GR	  are	  implicated	  in	  inflammation	  and	  cardiac	  remodelling	  following	  myocardial	  
injury.	  What	  is	  the	  cell-­‐specific	  role	  of	  GR	  in	  heart	  disease?	  This	  has	  not	  yet	  been	  
fully	  established	  and	  will	  be	  an	  important	  area	  for	  future	  investigation.	  	  
• Is	  the	  balance	  between	  GR	  and	  MR	  activity	  critical	  for	  cardiac	  health?	  Unpicking	  the	  
yin-­‐yang	  relationship	  between	  GR	  and	  MR	  in	  cardiomyocytes,	  particularly	  with	  
respect	  to	  ion	  channel	  regulation,	  will	  provide	  new	  insight	  into	  the	  relationship	  
between	  corticosteroids	  and	  cardiac	  disease.	  	  
• What	  is	  the	  role	  of	  the	  glucocorticoid	  metabolising	  enzyme,	  11β-­‐HSD1,	  in	  regulating	  
intracellular	  availability	  of	  glucocorticoid	  ligand	  to	  MR	  and	  GR	  in	  the	  heart?	  	  
• Can	  manipulation	  of	  cardiac	  GR	  signalling	  have	  therapeutic	  benefits	  in	  cardiac	  
pathologies?	  If	  so,	  which	  cardiac	  cell-­‐types	  should	  be	  targeted	  and	  what	  is	  the	  
appropriate	  time	  window?	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